BSE Live
Oct 24, 16:01Prev. Close
525.60
Open Price
524.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 24, 15:47Prev. Close
524.15
Open Price
527.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Lincoln Pharmaceuticals (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 376.84 | 356.92 | 356.02 | 355.38 | 396.59 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 1.02 | 5.08 | 5.86 | |
| Revenue From Operations [Net] | 376.84 | 356.92 | 355.00 | 350.29 | 390.72 | |
| Total Operating Revenues | 386.49 | 366.18 | 360.61 | 360.26 | 400.15 | |
| Other Income | 11.04 | 5.65 | 5.45 | 2.73 | 7.36 | |
| Total Revenue | 397.53 | 371.83 | 366.07 | 362.99 | 407.51 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 133.73 | 113.20 | 91.55 | 53.61 | 71.79 | |
| Purchase Of Stock-In Trade | 57.60 | 51.75 | 103.94 | 170.62 | 210.11 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 20.30 | 18.85 | 18.47 | |
| Changes In Inventories Of FGWIP And Stock In Trade | -8.41 | 10.46 | -2.98 | -6.64 | -4.45 | |
| Employee Benefit Expenses | 58.65 | 51.90 | 51.15 | 37.59 | 28.83 | |
| Finance Costs | 2.02 | 4.00 | 5.41 | 6.66 | 9.96 | |
| Depreciation And Amortisation Expenses | 7.33 | 6.68 | 6.11 | 5.51 | 4.87 | |
| Other Expenses | 79.39 | 71.66 | 44.33 | 39.45 | 34.86 | |
| Total Expenses | 330.30 | 309.64 | 319.82 | 325.66 | 374.45 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 67.23 | 62.19 | 46.25 | 37.33 | 33.07 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 67.23 | 62.19 | 46.25 | 37.33 | 33.07 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 15.67 | 15.08 | 10.38 | 7.75 | 6.94 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 0.04 | -1.63 | 1.21 | 1.45 | 2.32 | |
| Other Direct Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 15.77 | 13.46 | 11.60 | 9.20 | 9.27 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 51.47 | 48.74 | 34.65 | 28.13 | 23.80 | |
| Profit/Loss From Continuing Operations | 51.47 | 48.74 | 34.65 | 28.13 | 23.80 | |
| Profit/Loss For The Period | 51.47 | 48.74 | 34.65 | 28.13 | 23.80 | |
| Minority Interest | -0.03 | -0.03 | -0.03 | -0.01 | -0.12 | |
| Consolidated Profit/Loss After MI And Associates | 51.44 | 48.71 | 34.62 | 28.12 | 23.68 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 26.00 | 24.00 | 17.00 | 16.00 | 15.00 | |
| Diluted EPS (Rs.) | 26.00 | 24.00 | 17.00 | 16.00 | 14.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 6.00 | 3.00 | 2.40 | 1.63 | 1.63 | |
| Tax On Dividend | 1.23 | 0.62 | 0.49 | 0.33 | 0.33 |
07.08.2025
Lincoln Pharma Standalone June 2025 Net Sales at Rs 154.07 crore, up 4.61% Y-o-Y
24.06.2025
Lincoln Pharma Consolidated March 2025 Net Sales at Rs 168.18 crore, up 18.03% Y-o-Y
04.03.2025
Lincoln Pharma Consolidated December 2024 Net Sales at Rs 146.55 crore, up 0.07% Y-o-Y
28.11.2024
Lincoln Pharma Consolidated September 2024 Net Sales at Rs 161.21 crore, up 3.35% Y-o-Y
07.08.2025
Lincoln Pharma Standalone June 2025 Net Sales at Rs 154.07 crore, up 4.61% Y-o-Y
24.06.2025
Lincoln Pharma Consolidated March 2025 Net Sales at Rs 168.18 crore, up 18.03% Y-o-Y
04.03.2025
Lincoln Pharma Consolidated December 2024 Net Sales at Rs 146.55 crore, up 0.07% Y-o-Y
28.11.2024
Lincoln Pharma Consolidated September 2024 Net Sales at Rs 161.21 crore, up 3.35% Y-o-Y